GlassScriptPhysician profile
David Michael Gordon
NPI 1760724603
$28,278.28
in general payments reported to CMS, 2019-2025
54 companies · $2,663 in 2025
The $2,663 reported for 2025 was more than what 83% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,755 · 2020: $1,596 · 2021: $4,702 · 2022: $2,330 · 2023: $4,647 · 2024: $8,587 · 2025: $2,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,918 · Consulting Fee: $5,313 · Travel and Lodging: $1,646 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,918.38 |
| Consulting Fee | $5,312.50 |
| Travel and Lodging | $1,646.47 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,886.27 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Accolade Sr |
| Medtronic, INC. | $3,583.76 | 2021-2024 | Synchromedii, Intellis Adaptivestim, Vanta Adaptivestim |
| Abbott Laboratories | $2,279.71 | 2019-2025 | Proclaim |
| Abbvie INC. | $2,210.47 | 2021-2025 | |
| Si-Bone, INC. | $1,465.09 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $1,395.59 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $1,320.64 | 2019-2025 | Xtampza, Belbuca |
| Vertiflex, INC. | $1,240.60 | 2019 | |
| Vertos Medical, INC. | $788.87 | 2021-2024 | Mild Device Kit |
| Relievant Medsystems, INC. | $627.18 | 2021-2023 | Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $416.46 | 2019-2025 | Relistor |
| Tersera Therapeutics LLC | $331.36 | 2019-2025 | Prialt |
| Pacira Therapeutics, INC. | $324.87 | 2020-2021 | |
| Allergan, INC. | $310.42 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $285.68 | 2019-2021 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $267.37 | 2023-2025 | Prospera, Biotronik |
| Mml US, INC. | $227.69 | 2024-2025 | Reactiv8 |
| Amgen INC. | $202.60 | 2021-2022 | |
| Lundbeck LLC | $188.57 | 2024-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $148.66 | 2019-2025 | Austedo Xr, Austedo Xr |
| Stryker Corporation | $145.27 | 2025 | Mild Device Kit |
| Saluda Medical Americas, INC. | $141.00 | 2025 | Evoke |
| Spr Therapeutics, INC | $133.32 | 2019-2023 | Sprint Pns System |
| Scilex Pharmaceuticals INC. | $124.51 | 2019-2025 | |
| Nevro Corp. | $109.42 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $86.33 | 2023-2025 | Horizant, Horizant |
| Almatica Pharma LLC | $84.71 | 2021-2022 | |
| Redhill Biopharma INC. | $84.51 | 2020-2021 | |
| Lilly USA, LLC | $78.94 | 2021-2022 | |
| Orexo US, INC. | $72.81 | 2022-2025 | Zubsolv |
| Grt US Holding, INC. | $72.28 | 2021 | |
| Pfizer INC. | $55.33 | 2019-2023 | |
| Curonix LLC | $54.25 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biodelivery Sciences International, INC. | $49.64 | 2020-2021 | |
| Horizon Therapeutics Plc | $48.23 | 2020 | |
| Currax Pharmaceuticals LLC | $44.01 | 2020-2022 | |
| Spinefrontier, INC. | $37.84 | 2020 | |
| Ibsa Pharma INC. | $32.72 | 2021-2024 | Tirosint, Licart |
| Impel Pharmaceuticals INC. | $26.43 | 2023 | Trudhesa |
| Neurocrine Biosciences, INC. | $26.38 | 2024 | Ingrezza |
| Ossur Americas, INC. | $25.57 | 2024 | Miami J |
| Convatec INC. | $23.61 | 2024 | |
| Assertio Therapeutics, INC. | $23.45 | 2019 | |
| Mdd US Operations, LLC | $23.14 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $21.84 | 2025 | Purified Cortrophin Gel |
| Vertex Pharmaceuticals Incorporated | $21.77 | 2024 | |
| Supernus Pharmaceuticals, INC. | $20.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.14 | 2021 | |
| Bioventus LLC | $17.19 | 2022 | |
| Depuy Synthes Sales INC. | $15.98 | 2021 | |
| Fidia Pharma USA INC. | $14.30 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.09 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.08 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.